Effects of Plasma Albumin on the Pharmacokinetics of Esomeprazole in ICU Patients

Table 1

Demographic characteristics of patients.

		LPAG (26.29 ±3.55, n=19)	HPAG (34.82 ±3.05, n=13)	P
Gender	male, n ( % )	13 (63.16)	9 (69.23)	0.72
APACHE II		20.42 (8.55)	20.23 (8.65)	0.95
Age	mean (s.d.), years	64.3 (19.1)	55.6 (20.4)	0.24
Weight	mean (s.d.), kg	61.74 (9.73)	61.92 (13.00)	0.96
Height	mean (s.d.), cm	162.89 (8.39)	166.85 (26.84)	0.19
ALT	mean (s.d.), U/L	39.58 (26.59)	52.77 (38.45)	0.34
AST	mean (s.d.), U/L	54.58 (44.49)	49.38 (41.18)	0.75
BUN	mean (s.d.), mmol/L	11.35 (9.66)	6.62 (6.19)	0.03
CCR	mean (s.d.), mL/min	76.26 (49.03)	117.19 (53.94)	0.03
Baseline hemoglobin	< 9 g / dl, n (%)	12 (57.14)	4 (30.77)	0.07
CYP2C19 normal metabolizer (NM)		9 (47.62)	4 (30.77)	0.35
CYP2C19 intermediate metabolizer (IM)		10 (47.62)	6 (46.15)	0.72
CYP2C19 poor metabolizer (PM)		0 (0.00)	3 (23.08)

ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urine nitrogen; CCR, creatinine clearance rate.